In a phase I clinical trial, a high tumor/organ ratio (higher than 20) after phenotypic imaging (111In-IMP288-TF2) has been demonstrated, highlighting that CEA-expression of normal organs is not a limitation for TF2-pretargeting [26]. This evidence concerns the gene CEACAM5 and neoplasm.